Pfizer (PFE) Tops Q1 EPS by 24c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
JPMorgan Reiterates Neutral Rating on Pfizer (PFE)
April 29, 2025 4:14 PM EDTJPMorgan analyst Chris Schott reiterated a Neutral rating and $30.00 price target on Pfizer (NYSE: PFE).
The analyst comments "Exiting PFEs 1Q results and our follow up with the company, we want to provide our key takeaways. On the qtr, PFE's sales came in below expectations (which is not surprising as... More
